Machine learning prioritizes compounds active against heterogeneous glioblastoma stem-cell models
Researchers trained cell-survival predictors on image-based screening data from six patient-derived glioblastoma stem-cell lines and screened more than 12,000 compounds. Experimental follow-up identified three compounds with activity across the GBM phenotype; HSP90 inhibitor XL-888 eliminated all six tested lines at nanomolar IC50 values, with analyses consistent with HSP90 inhibition and downstream client-protein disruption.
Technology: Machine-learning cell-survival predictors trained on high-throughput phenotypic screening
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Experimental follow-up identified three compounds with activity across the GBM phenotype; HSP90 inhibitor XL-888 eliminated all six tested lines at nanomolar IC50 values, with analyses consistent with HSP90 inhibition and downstream client-protein disruption.
- Still unknown: This is an in-vitro lead-discovery study across six patient-derived cell lines, not clinical efficacy. XL-888 is an existing HSP90 inhibitor and its proposed development as a GBM lead needs medicinal-chemistry optimization, including improved blood–brain-barrier penetration; no patient outcomes are reported.
- AI role: ML models trained on in-house imaging/compound-response data predicted cell survival and prioritized compounds from a >12,000-compound screen; experimental assays across patient-derived GBM stem-cell models validated three leads and tested mechanisms. Researchers performed the wet-lab work and mechanism analyses.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/42158926/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.